Combination of anti-KIR and anti-CTLA-4 antibodies to treat cancer

A method of treating a solid tumor in a human patient diagnosed with non-small cell lung cancer (NSCLC), castrate resistant prostate cancer (CRPC) and/or melanoma, the method comprising:

• administering to the patient an effective amount of each of:
• (a) an anti-KIR antibody comprising the CDR1, CDR2 and CDR3 domains in a heavy chain variable region having the sequences set forth in SEQ ID NO:3, and the CDR1, CDR2 and CDR3 domains in a light chain variable region having the sequences set forth in SEQ ID NO:5 and
• (b) an anti-CTLA-4 antibody comprising the CDR1, CDR2 and CDR3 domains in a heavy chain variable region having the sequences set forth in SEQ ID NO:19, and the CDR1, CDR2 and CDR3 domains in a light chain variable region having the sequences set forth in SEQ ID NO:20,
• wherein the anti-KIR antibody and anti-CTLA-4 antibody are administered in combination (A) every 3 weeks for a total of 4 doses over 12 weeks during an induction phase, followed by (B) every 12 weeks for 4 doses starting at week 24 during a maintenance phase, and
• wherein the anti-KIR antibody is administered at a dose of 0.1, 0.3, 1, 3 or 10 mg/kg, and the anti-CTLA-4 antibody is administered at a dose of 3 or 10 mg/kg during both phases.